Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab and Pentostatin in T-Cell Neoplasms
NCT00453193Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2004
- Primary completion
- Mar 2010
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab and pentostatin in T-cell neoplasms, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants With Objective Response at 6 months. Started Sep 2004; status: terminated.
02
Drugs
alemtuzumabpentostatin
03
Conditions
T-cell neoplasms
Beyond the preview
Go deeper on NCT00453193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00453193.